NasdaqGS - Nasdaq Real Time Price USD

Alnylam Pharmaceuticals, Inc. (ALNY)

235.16

-5.39

(-2.24%)

As of 1:25:26 PM EST. Market Open.

Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., January 06, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. As part of the presentation, the Company will discuss unaudited fourth quarter and full year 2024 global net product revenues.

Business Wire 4 days ago

ALNY
-2.24%
Exploring High Growth Tech Stocks in the US December 2024

The United States market has recently experienced a 2.8% increase over the past week and a substantial 24% climb over the last year, with earnings expected to grow by 15% per annum in the coming years. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to leverage these favorable market conditions.

Simply Wall St. 15 days ago

ALNY
-2.24%
COHR

SRPT
-1.00%
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?

Here is how Alnylam Pharmaceuticals (ALNY) and argenex SE (ARGX) have performed compared to their sector so far this year.

Zacks 16 days ago

ALNY
-2.24%
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Performing Biotech Stock in 2024?

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands against the other biotech stocks. The Booming Biotechnology Sector The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, […]

Insider Monkey 18 days ago

ALNY
-2.24%
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam

Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam are included in this Analyst Blog.

Zacks 21 days ago

EXEL
+2.51%
ALNY
-2.24%
SRPT
-1.00%
4 Biotech Stocks Most Wall Street Analysts Are Bullish About

Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals.

Zacks 22 days ago

EXEL
+2.51%
ALNY
-2.24%
SRPT
-1.00%
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study

Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients.

Zacks 30 days ago

ALNY
-2.24%
PFE
What Makes Alnylam (ALNY) a New Buy Stock

Alnylam (ALNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks last month

ALNY
-2.24%
Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?

Here is how Sensus Healthcare, Inc. (SRTS) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.

Zacks last month

SRTS

ALNY
-2.24%
Why Is Alnylam Pharmaceuticals, Inc. (ALNY) Among the Best High Growth Healthcare Stocks to Invest In Now?

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands against the other high growth healthcare stocks. Global Healthcare Spending Trends and Investment Opportunities During lean economic times, investing in healthcare stocks […]

Insider Monkey last month

ALNY
-2.24%
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

CAMBRIDGE, Mass., November 27, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 11:00 am ET at the Lotte New York Palace Hotel in New York City.

Business Wire last month

ALNY
-2.24%
Kronos, Idorsia plan layoffs; PTC shelves ALS drug

Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC disclosed negative Phase 2 results for its ALS drug candidate utreloxastat.

BioPharma Dive last month

IDIA.SW

PTCT
-0.33%
KRON
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use

ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.

Zacks last month

ALNY
-2.24%
BBIO

NVS
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.

Investor's Business Daily last month

NTLA

BBIO

PFE
Exploring Three High Growth Tech Stocks In The United States

The United States market has shown robust performance, climbing by 2.2% over the past week with all sectors experiencing gains, and achieving a 32% increase over the last 12 months, while earnings are projected to grow by 15% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and scalability to capitalize on these favorable market conditions.

Simply Wall St. last month

GLOB

ALNY
-2.24%
GILD
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass., November 25, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental New Drug Application (sNDA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Based on the Company’s use of a Priority Review Voucher, the FDA has set an action date goal of Ma

Business Wire last month

ALNY
-2.24%
BridgeBio heart drug approved by FDA, setting up battle with Pfizer

BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved with a broad label that looks competitive to Pfizer's tafamidis.

BioPharma Dive last month

BBIO

PFE

ALNY
-2.24%
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study

Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.

Zacks last month

ALNY
-2.24%
PFE
Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment

The study showed significant reductions in serum TTR levels in subjects after a single dose, with sustained effects over time.

Clinical Trials Arena last month

ALNY
-2.24%
Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

CAMBRIDGE, Mass., November 17, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucresiran (formerly ALN-TTRsc04), a next-generation RNAi therapeutic in development for the treatment of transthyretin (ATTR) amyloidosis. The data were presented in an oral session at the American Heart Association Scientific Sessions 2024 in Chicago.

Business Wire last month

ALNY
-2.24%

Performance Overview

Return	ALNY	S&P 500
YTD	-0.36%	-0.87%
1-Year	+18.65%	+23.11%
3-Year	+58.75%	+25.20%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Exploring High Growth Tech Stocks in the US December 2024

Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?

Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Performing Biotech Stock in 2024?

The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam

4 Biotech Stocks Most Wall Street Analysts Are Bullish About

CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study

What Makes Alnylam (ALNY) a New Buy Stock

Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?

Why Is Alnylam Pharmaceuticals, Inc. (ALNY) Among the Best High Growth Healthcare Stocks to Invest In Now?

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

Kronos, Idorsia plan layoffs; PTC shelves ALS drug

FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

Exploring Three High Growth Tech Stocks In The United States

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

BridgeBio heart drug approved by FDA, setting up battle with Pfizer

ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study

Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

Performance Overview